Correction to: Health care providers’ support of patients’ autonomy, phosphate medication adherence, race and gender in end-stage renal disease

IntroductionPeritoneal dialysis (PD) is occasionally used in western sub-Saharan Africa to treat patients with end-stage renal disease (ESRD). The present study is a retrospective review of the initial six years’ experience with PD for ESRD therapy in Senegal, a West African country with a population of over 12 million.Material and MethodsSingle-center retrospective cohort study of patients treated with PD between March 2004 and December 2010. Basic demographic data were collected on all patients. Peritonitis rates, causes of death and reasons for transfer to hemodialysis (HD) were determined in all patients.ResultsSixty-two patients were included in the study. The median age was 47 ± 13 years with a male/female ratio of 1.21. Nephrosclerosis and diabetic nephropathy were the main causes of ESRD. The mean Charlson score was 3 ± 1 with a range of 2 to 7. Forty five peritonitis episodes were diagnosed in 36 patients (58%) for a peritonitis rate of 1 episode/20 patient-months (0.60 episodes per year). Staphylococcus aureus and Pseudomonas aeruginosa were the most commonly identified organisms. Touch contamination has been implicated in 26 cases (57.7%). In 23 episodes (51%), bacterial cultures were negative. Catheter removal was necessary in 12 cases (26.6%) due to mechanical dysfunction, fungal or refractory infection. Sixteen patients died during the study.ConclusionPeritoneal dialysis is a suitable therapy which may be widely used for ESRD treatment in western sub-Saharan Africa. A good peritonitis rate can be achieved despite the difficult living conditions of patients. Challenges to the development of PD programs include training health care providers, developing an infrastructure to support the program, and developing a cost structure which permits expansion of the PD program.

Download Full-text

A study on knowledge of patients with end stage renal disease towards dialysis in a tertiary care hospital in Dhaka city

IMC Journal of Medical Science ◽

10.3329/imcjms.v11i1.31932 ◽

2017 ◽

Vol 11 (1) ◽

pp. 11-14 ◽

Cited By ~ 1

Author(s):

Tufayel Ahmed Chowdhury ◽

Sarwar Iqbal ◽

Umme Salma Talukder ◽

Mehruba Alam Ananna ◽

ASM Manzur Morshed Bhuiyan ◽

...

Keyword(s):

Renal Disease ◽

Prior Knowledge ◽

Health Care Providers ◽

End Stage Renal Disease ◽

Public Awareness ◽

Tertiary Care ◽

Care Hospital ◽

Care Providers ◽

Stage Renal Disease ◽

End Stage

Background and objective: There are approximately two million patients suffering from end stage renal disease (ESRD) worldwide requiring renal replacement therapy (RRT) in the form of dialysis. There are very few statistics regarding the knowledge and attitude towards dialysis among ESRD patients in Bangladesh. The present study was undertaken to understand the existing knowledge of the patients with ESRD regarding dialysis.Methods: This cross sectional descriptive study was done on 104 patients with ESRD requiring immediate dialysis. This study was conducted in the department of Nephrology, BIRDEM General Hospital, Dhaka, Bangladesh over a period of six months. After obtaining informed consent the participants were given a self-administered questionnaire that included questions on socio-demographic status, age, gender, different aspects of knowledge about dialysis and the reasons to accept and refuse dialysis for the treatment of ESRD.Results: A total of 104 patients with ESRD were enrolled in the study. The mean age was 54.20(±11.82) years, 87.5% were more than 40 years of age, and 72.1% were male. Eighty two percent mentioned diabetes as the cause of kidney disease. About half of the respondents (52.88%) knew dialysis as an option for the treatment of ESRD followed by kidney transplant (11.54%). A few (7.3%) mentioned medicine and dietary modification as the treatment. There was no statistical association between prior knowledge and agreeing to do dialysis (?2= 0.7814; p=0.376699). Most of the patients (78%) gathered knowledge about dialysis from doctors. Seventy two patients (69.2%) agreed to do dialysis. Among them 37 patients (51.4%) agreed as they considered it as a part of treatment and 32 patients (44.4%) agreed because they were advised by doctors. Reasons for refusal to do dialysis were - fear of death (59.37%), financial constraints (31.25%) and lack of availability of dialysis centre (9.37%) Among study populations, only 20 patients (19.2%) mentioned about peritoneal dialysis (PD) and all of them (100%) were informed by doctors.Conclusion: The present study has demonstrated that prior knowledge on dialysis has no influence on the decision to do dialysis for the treatment of ESRD. Availability and access to dialysis facility and counseling on beneficial aspects of dialysis is required to motivate the patients for dialysis with ESRD. In addition to health care providers, social media may play an important role in promoting public awareness regarding dialysis as a treatment modality of ESRD.IMC J Med Sci 2017; 11(1): 11-14

Download Full-text

An Overview of Diabetic Nephropathy

Journal of Pharmacy Practice ◽

10.1177/0897190003261312 ◽

2004 ◽

Vol 17 (1) ◽

pp. 75-79 ◽

Cited By ~ 6

Author(s):

Kenyetta N. Nesbitt

Keyword(s):

Health Care ◽

Diabetic Nephropathy ◽

Renal Disease ◽

End Stage Renal Disease ◽

Angiotensin Receptor Blockers ◽

The United States ◽

Care Providers ◽

Stage Renal Disease ◽

End Stage ◽

Progression Of Renal Disease

Diabetic nephropathy is a complication of type 1 and type diabetes mellitus and the leading cause of end-stage renal disease in the United States. The health care system spends billions of dollars every year to treat end-stage renal disease patients. Health care providers must address diabetic nephropathy. The American Diabetes Association set forth recommendations for early detection to slow the progression of renal disease and treatment guidelines for patients with diabetes along with hypertension and diabetic nephropathy. Routine screening and treatment are the key to ending the trend of patients with diabetic nephropathy progressing to end-stage renal disease. Glycemic and blood pressure control is important for managing diabetic nephropathy. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers have become drugs of choice for treating diabetic nephropathy, based on clinical studies showing they slow the progression of renal disease. Whether protein restrictions are necessary in patients with diabetic nephropathy is being debated.

Download Full-text

Associations between health literacy and health care utilization and mortality in patients with coexisting diabetes and end‐stage renal disease: A prospective cohort study

British Journal of Health Psychology ◽

10.1111/bjhp.12413 ◽

2020 ◽

Vol 25 (3) ◽

pp. 405-427

Author(s):

Konstadina Griva ◽

Russell K. L. Yoong ◽

Mooppil Nandakumar ◽

Moothathamby Rajeswari ◽

Eric Y. H. Khoo ◽

...

Keyword(s):

Health Care ◽

Cohort Study ◽

Health Literacy ◽

Renal Disease ◽

Health Care Utilization ◽

End Stage Renal Disease ◽

Prospective Cohort ◽

Care Utilization ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Single-Dose Pharmacokinetics, Safety, and Tolerability of Albinterferon Alfa-2b in Subjects with End-Stage Renal Disease on Hemodialysis Compared to Those in Matched Healthy Volunteers

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00626-10 ◽

2010 ◽

Vol 55 (2) ◽

pp. 473-477 ◽

Cited By ~ 1

Author(s):

Denise B. Serra ◽

Haiying Sun ◽

Sylwia Karwowska ◽

Jens Praestgaard ◽

Atef Halabi ◽

...

Keyword(s):

Renal Disease ◽

Healthy Volunteers ◽

End Stage Renal Disease ◽

Hepatitis C Virus Infection ◽

Time Curve ◽

And Gender ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients ◽

Laboratory Adverse Event

ABSTRACTAlbinterferon alfa-2b (albIFN) is being developed, in combination with ribavirin, for the treatment of hepatitis C virus infection. This study was designed to evaluate the pharmacokinetics, safety, and tolerability of a 900-μg dose of albIFN administered as a single subcutaneous injection in end-stage renal disease (ESRD) patients on hemodialysis and matched healthy volunteers (by age [±5 years], weight [±5 kg], and gender). The maximum concentration in plasma (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0-∞) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while theCmaxand AUC0-∞were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients. The geometric least-squares mean ratios were 1.15 (90% confidence interval [CI], 0.78, 1.68) forCmaxand 1.11 (90% CI, 0.83, 1.48) for AUC0-∞. Adverse events were as expected for an interferon (e.g., flu-like symptoms), with the main laboratory adverse event being a decline in total white blood cell count, which was specifically related to a decline in the neutrophil count. This effect was somewhat greater in the ESRD patients, with the maximal decreases in neutrophil counts from those at the baseline being (−2.6 ± 0.32) × 109and (−2.19 ± 0.58) × 109cells/liter for the ESRD patients and the healthy volunteers, respectively. This study indicates no significant effect of renal failure on the pharmacokinetics of albIFN. Safety and tolerability were as expected for an interferon.

Download Full-text